UA99476C2 - 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors - Google Patents

2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors

Info

Publication number
UA99476C2
UA99476C2 UAA201003977A UAA201003977A UA99476C2 UA 99476 C2 UA99476 C2 UA 99476C2 UA A201003977 A UAA201003977 A UA A201003977A UA A201003977 A UAA201003977 A UA A201003977A UA 99476 C2 UA99476 C2 UA 99476C2
Authority
UA
Ukraine
Prior art keywords
deoxytetrahydrouridines
fluoro
cytidine deaminase
deaminase inhibitors
compounds
Prior art date
Application number
UAA201003977A
Other languages
English (en)
Ukrainian (uk)
Inventor
Грегори С. Гамильтон
Такаши Цукамото
Дейна В. Феррарис
Бриджет Дювалл
Рина Лапидус
Original Assignee
Эйсай Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйсай Инк. filed Critical Эйсай Инк.
Publication of UA99476C2 publication Critical patent/UA99476C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Изобретение относится к соединениям, которые являются производными тетрагидроуридина, и фармацевтических композиций, которые включают указанные соединения, а также к применению указанных соединений.
UAA201003977A 2007-10-16 2008-10-16 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors UA99476C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16

Publications (1)

Publication Number Publication Date
UA99476C2 true UA99476C2 (en) 2012-08-27

Family

ID=40251685

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201003977A UA99476C2 (en) 2007-10-16 2008-10-16 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors

Country Status (39)

Country Link
US (4) US8268800B2 (ru)
EP (2) EP2447272B1 (ru)
JP (2) JP5496899B2 (ru)
KR (1) KR101543049B1 (ru)
CN (1) CN101827856B (ru)
AT (1) ATE548374T1 (ru)
BR (1) BRPI0818672B8 (ru)
CA (1) CA2702274C (ru)
CO (1) CO6270330A2 (ru)
CR (1) CR11427A (ru)
CY (1) CY1112781T1 (ru)
DK (1) DK2207786T3 (ru)
EA (1) EA018757B1 (ru)
EC (1) ECSP10010095A (ru)
ES (2) ES2384011T3 (ru)
FI (2) FIC20230039I1 (ru)
FR (2) FR23C1051I1 (ru)
GT (1) GT201000088A (ru)
HK (1) HK1146410A1 (ru)
HR (1) HRP20120419T1 (ru)
HU (2) HUS2300045I1 (ru)
IL (1) IL204732A (ru)
JO (1) JO2778B1 (ru)
ME (1) ME00997B (ru)
MX (1) MX2010004109A (ru)
MY (1) MY147970A (ru)
NI (1) NI201000055A (ru)
NL (1) NL301256I2 (ru)
NO (2) NO2023048I1 (ru)
NZ (1) NZ584229A (ru)
PL (1) PL2207786T3 (ru)
PT (1) PT2207786E (ru)
RS (1) RS52323B (ru)
SA (1) SA08290661B1 (ru)
SI (1) SI2207786T1 (ru)
TW (1) TWI445539B (ru)
UA (1) UA99476C2 (ru)
WO (1) WO2009052287A1 (ru)
ZA (1) ZA201002178B (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
LT2299984T (lt) 2008-05-15 2019-03-25 Celgene Corporation Peroralinės citidino analogų kompozicijos ir jų naudojimo būdai
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
AR076263A1 (es) 2009-04-06 2011-06-01 Eisai Inc Composiciones y metodos para tratar cancer. uso.
ES2593088T3 (es) 2009-04-06 2016-12-05 Otsuka Pharmaceutical Co., Ltd. Derivados de (2'-Desoxi-Ribofuranosil)-1,3,4,7-Tetrahidro-(1,3)Diazepin-2-ona para Tratamiento de Cáncer
CA2757745C (en) * 2009-04-06 2018-02-13 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
SI3290428T1 (sl) 2010-03-31 2022-01-31 Gilead Pharmasset Llc Tableta, ki obsega kristalinični (S)-izopropil 2-(((S)-(((2R,3R,4R,5R) -5-(2,4-diokso-3,4-dihidropirimidin-1(2H)-il)-4-fluoro-3-hidroksi-4- metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
HUE036588T2 (hu) 2011-09-16 2018-07-30 Gilead Pharmasset Llc Eljárások HCV kezelésére
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
UA118256C2 (uk) 2013-01-31 2018-12-26 Гіліад Фармассет Елелсі Комбінований склад двох противірусних сполук
SG11201600919UA (en) 2013-08-27 2016-03-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
AU2014342402B2 (en) * 2013-10-29 2018-11-01 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
MX2017002382A (es) 2014-08-22 2017-05-17 Celgene Corp Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos.
CN109789155A (zh) 2015-12-03 2019-05-21 免疫规划公司 含有地西他滨、5-氮杂胞苷和四氢尿苷的组合物以及其用途
WO2017158396A1 (en) * 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
BR112020015745A2 (pt) 2018-02-02 2020-12-08 Maverix Oncology, Inc. Conjugados de fármacos de moléculas pequenas de monofosfato de gemcitabina
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
EP3868774A4 (en) * 2018-10-19 2023-05-10 Interoligo Corporation MODIFIED NUCLEIC ACID WITH IMPROVED TREATMENT EFFICIENCY AND ANTI-CANCER PHARMACEUTICAL COMPOSITION THEREOF
WO2020080912A1 (ko) * 2018-10-19 2020-04-23 인터올리고 주식회사 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
KR20220078619A (ko) * 2019-10-08 2022-06-10 오츠카 세이야쿠 가부시키가이샤 고순도의 2'-데옥시-2',2'-디플루오로테트라히드로우리딘 및 그의 제조 방법
KR20220145815A (ko) * 2020-02-25 2022-10-31 오츠카 세이야쿠 가부시키가이샤 조합 데시타빈 및 세다주리딘 고체 경구 투여 형태
EP4313069A1 (en) * 2021-03-26 2024-02-07 The Cleveland Clinic Foundation Treatment of rna virus infection with a cytidine deaminase inhibitor
WO2022254457A1 (en) * 2021-05-29 2022-12-08 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
WO2023069529A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
WO2023076332A1 (en) * 2021-11-01 2023-05-04 St. John's University Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
WO2024047394A1 (en) 2022-08-31 2024-03-07 Otsuka Pharmaceutical Co., Ltd. Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0160079B1 (en) 1983-10-26 1990-01-31 GREER, Sheldon B. Method and materials for sensitizing neoplastic tissue to radiation
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
EP0543976A4 (en) 1991-04-23 1993-11-10 Oglevee, Ltd. In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) * 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
CA2118490A1 (en) * 1993-02-23 1994-09-01 Lawrence C. Sowers 4-ethoxy 5-fluoro 2'deoxyuridine
AU6081294A (en) * 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
AU5300396A (en) * 1995-03-01 1996-09-18 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) * 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
ES2273672T3 (es) * 1999-03-01 2007-05-16 Halogenetics, Inc. Uso de composiciones que comprenden cldc como radiosensibilizadores en el tratamiento de enfermedades neoplasticas.
US6933287B1 (en) * 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
NZ517437A (en) 1999-08-26 2004-02-27 Omega Critical Care Ltd Improvements relating to catheter positioning
US6462191B1 (en) * 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
DE60144573D1 (de) * 2000-11-29 2011-06-16 Mitsui Chemicals Inc Verfahren und Zwischenprodukte bei der Synthese von L-Thymidin
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
CA2826505A1 (en) 2001-05-18 2002-11-28 Rakesh Kumar Antiviral nucleosides
EP1418949B1 (en) * 2001-07-31 2013-06-19 THE STATE OF OREGON acting by and through THE STATE BOARD OF HIGHER EDUCATION on behalf of THE UNIVERSITY OF OREGON Inhibitor of dna methylation
CN1646534A (zh) 2002-02-14 2005-07-27 法玛塞特有限公司 修饰的氟化核苷类似物
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
CA2499036A1 (en) 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
US8158770B2 (en) * 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
TW200606159A (en) 2004-07-30 2006-02-16 Pharmaessentia Corp Stereoselective synthesis of β-nucleosides
MX2007006837A (es) 2004-12-08 2007-10-23 Sicor Inc Difluoronucleosidos y proceso de preparacion de los mismos.
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
CA2757745C (en) * 2009-04-06 2018-02-13 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
ES2593088T3 (es) * 2009-04-06 2016-12-05 Otsuka Pharmaceutical Co., Ltd. Derivados de (2'-Desoxi-Ribofuranosil)-1,3,4,7-Tetrahidro-(1,3)Diazepin-2-ona para Tratamiento de Cáncer
AR076263A1 (es) * 2009-04-06 2011-06-01 Eisai Inc Composiciones y metodos para tratar cancer. uso.
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer

Also Published As

Publication number Publication date
NL301256I1 (ru) 2024-01-03
KR20100091978A (ko) 2010-08-19
BRPI0818672A2 (pt) 2015-04-14
JP2011500713A (ja) 2011-01-06
EP2447272A1 (en) 2012-05-02
NZ584229A (en) 2012-06-29
JP5859588B2 (ja) 2016-02-10
ME00997B (me) 2012-10-20
US8268800B2 (en) 2012-09-18
FIC20230040I1 (fi) 2023-12-22
IL204732A (en) 2013-07-31
TW200924786A (en) 2009-06-16
SI2207786T1 (sl) 2012-10-30
AU2008312435A1 (en) 2009-04-23
US9567363B2 (en) 2017-02-14
RS52323B (en) 2012-12-31
ZA201002178B (en) 2011-05-25
EP2447272B1 (en) 2017-02-01
ATE548374T1 (de) 2012-03-15
MY147970A (en) 2013-02-28
KR101543049B1 (ko) 2015-08-07
ES2616566T3 (es) 2017-06-13
US20150210730A1 (en) 2015-07-30
CA2702274C (en) 2015-12-29
JP2014177455A (ja) 2014-09-25
WO2009052287A1 (en) 2009-04-23
EP2207786A1 (en) 2010-07-21
AU2008312435A8 (en) 2014-07-24
SA08290661B1 (ar) 2012-06-10
US20090137521A1 (en) 2009-05-28
CN101827856A (zh) 2010-09-08
CA2702274A1 (en) 2009-04-23
NO2023047I1 (no) 2023-12-21
US20120289475A1 (en) 2012-11-15
PT2207786E (pt) 2012-05-28
TWI445539B (zh) 2014-07-21
CN101827856B (zh) 2013-02-06
JP5496899B2 (ja) 2014-05-21
GT201000088A (es) 2012-03-13
US8951987B2 (en) 2015-02-10
PL2207786T3 (pl) 2012-09-28
AU2008312435B2 (en) 2014-04-17
HUS2300044I1 (hu) 2024-01-28
CR11427A (es) 2010-08-16
MX2010004109A (es) 2010-08-10
CY1112781T1 (el) 2016-02-10
HRP20120419T1 (hr) 2012-07-31
JO2778B1 (en) 2014-03-15
BRPI0818672B1 (pt) 2020-10-20
BRPI0818672B8 (pt) 2021-05-25
NI201000055A (es) 2010-08-13
FR23C1052I1 (fr) 2024-01-26
HK1146410A1 (en) 2011-06-03
CO6270330A2 (es) 2011-04-20
US8618075B2 (en) 2013-12-31
FR23C1051I1 (fr) 2024-01-26
NL301256I2 (nl) 2024-01-11
ES2384011T3 (es) 2012-06-28
US20140186335A1 (en) 2014-07-03
NO2023048I1 (en) 2023-12-21
IL204732A0 (en) 2010-11-30
EP2207786B1 (en) 2012-03-07
ECSP10010095A (es) 2010-07-30
HUS2300045I1 (hu) 2024-01-28
EA201000642A1 (ru) 2010-10-29
EA018757B1 (ru) 2013-10-30
DK2207786T3 (da) 2012-06-18
FIC20230039I1 (fi) 2023-12-22

Similar Documents

Publication Publication Date Title
UA99476C2 (en) 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors
UA97502C2 (ru) Кристаллическая твердая основа разагилина
EP2061476A4 (en) COMPOSITIONS WITH CDP-CHOLINE AND METHOD OF USE THEREOF
TW200634023A (en) Amide prodrug of gemcitabine, compositions and use thereof
WO2008049116A3 (en) Substituted indoles
NO20090596L (no) Antivirale fosfinatforbindelser
TW200740814A (en) Compounds
WO2008013589A3 (en) Treatment of ras-expressing tumors
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
TW200716130A (en) Purified form of tanaproget
MX2009000198A (es) Formas cristalinas de profarmaco amida de gemcitabina, composiciones y usos del mismo.
WO2008107771A3 (en) 2',3'-di-o-acyl-5-fluoronucleosides
MX2009009074A (es) Macrolidos basados en eritromicina.
HK1131609A1 (en) Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof
HK1131156A1 (en) Novel morphine derivatives
AU2015201137B2 (en) Compositions and method for tissue preservation
UA97521C2 (ru) и-РНК-АГЕНТ, КОТОРЫЙ ОПОСРЕДУЕТ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC